HALO - Halozyme Therapeutics authorizes $750M share repurchase program

Halozyme Therapeutics (NASDAQ:HALO) has announced a new share repurchase program to buyback up to $750M of its outstanding common stock over the next three years. The program follows the recent completion of the company's previous $550M three-year share repurchase program. The biopharmaceutical firm plans to enter into an accelerated share repurchase (ASR) program transaction with a financial institution in the coming week. By the end of 2022, it plans to buy up to $250M worth of shares, including the $150M ASR. Read a recent bullish analysis on HALO, where Kolomeets Investments estimates an upside potential to the fair price of 25%.

For further details see:

Halozyme Therapeutics authorizes $750M share repurchase program